Why Experts Say Lupus Research Is Entering a New Era

For patients living with lupus, the pace of treatment innovation is beginning to feel very different from what it was even a decade ago. According to Albert T. Roy, president and CEO of the Lupus Research Alliance, the recent U.S. Food and Drug Administration acceptance of Genentech’s supplemental biologics license application for Gazyva (obinutuzumab) for systemic lupus erythematosus (SLE) represents more than just another drug application — it reflects growing momentum in lupus research and treatment development.

Roy explained that for decades, lupus patients had very few new treatment options. After the approval of Benlysta in 2011, there was another long stretch with little progress. Since 2021, however, several therapies have been approved for lupus and lupus nephritis, creating what Roy described as a major shift in the field. He emphasized that lupus is an incredibly complex and heterogeneous disease, meaning no single treatment works for every patient. Because symptoms and disease activity vary widely from person to person, having more therapies available gives physicians more flexibility to tailor care to individual needs.

One of the most promising developments, Roy said, is the move toward more precise treatments that target specific immune system pathways instead of broadly suppressing the entire immune system. Historically, many lupus medications worked by dampening immune activity overall, which could leave patients vulnerable to infections and other complications. Newer therapies, including biologics and emerging cellular therapies like CAR-T cell approaches, are designed to focus more specifically on the immune cells driving disease activity.

Roy noted that this precision-medicine approach could potentially improve outcomes while reducing some of the long-term side effects patients often experience with traditional immunosuppressive medications. He also highlighted growing excitement around therapies originally developed in cancer research that are now being explored for autoimmune diseases like lupus.

Another major shift happening in lupus research involves steroid use. Corticosteroids such as prednisone have long been used to quickly control inflammation during lupus flares, but Roy explained that chronic steroid use can cause significant long-term harm. Researchers and drug developers are now intentionally designing clinical trials to reduce patients’ dependence on steroids while evaluating new therapies.

In many newer lupus studies, patients are required to taper down steroid doses during the trial. According to Roy, this helps researchers better determine whether investigational drugs are truly controlling disease activity on their own. More importantly, it reflects a broader goal within lupus care: helping patients maintain disease control while minimizing exposure to steroids whenever possible.

For patients, Roy believes the growing pipeline of therapies offers real hope. While no cure currently exists, the expanding number of treatment options may allow more people with lupus to better manage symptoms, reduce flare activity and improve quality of life over time.